Michele Rossi

Dr. Michele Rossi


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2022
Verified
Book Chapter
Closed access
PDF file
SDShoumitro Shoumi Deb
Shoumitro Shoumi Deb
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
MRMichele Rossi
Michele Rossi

18 March 2025 in Brain Sciences
Verified
Journal Article
Open access
PDF file
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
ABAnnamaria Bianco
Annamaria Bianco
MMMicaela Piva Merli
Micaela Piva Merli
MVMaria Stella Vescio
Maria Stella Vescio
MRMichele Rossi
Michele Rossi
EBElisabetta F. Buonaguro
Elisabetta F. Buonaguro
Background/Objectives: First-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) are frequently prescribed for the management of problem behaviours (PBs) in people with intellectual developmental disorders (IDDs) with or without autism spectrum disorder (ASD). However, the different effectiveness of these two groups of drugs has not been adequately investigated, especially in terms of person-centred outcomes, such as quality of life (QoL). The aim of the present observational study was to compare the personal QoL of two groups of people with IDDs with and without ASD, attending the same residential facility, but receiving FGAs and SGAs, respectively, for the management of PBs. Methods: Twenty-two people with IDDs (ten with ASD) receiving FGAs and twenty-three (eleven with ASD) receiving SGAs for the management of PBs were consecutively recruited. The participants underwent a complex clinical and instrumental evaluation, including the systematic psychopathological assessment for persons with intellectual and developmental disabilities—general screening (SPAIDD-G), the Wing’s handicaps, behaviours, and skills schedule (HBS), the DOTES, and the BASIQ (QoL Assessment tool battery). Follow-up evaluations were carried out after 6, 12, and 18 months. Results: The use of antipsychotics was withdrawn only in 16 cases, of which only 4 were for significant improvement. Treatment with FGAs was associated with more frequent discontinuation, a higher incidence of side effects, and a trend toward a lower efficacy on PBs than treatment with SGAs. FGAs also improved generic QoL significantly less than SGAs. Conclusions: The present pilot study is the first to compare FGAs and SGAs with respect to the generic QoL in people with IDDs and PBs. SGAs resulted to have a significantly greater positive impact on QoL than FGAs, despite demonstrating similar efficacy in treating PBs.

12 May 2022
Verified
Book Chapter
Closed access
PDF file
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
ABAnnamaria Bianco
Annamaria Bianco
EBElisabetta Filomena Buonaguro
Elisabetta Filomena Buonaguro
MMMicaela Piva Merli
Micaela Piva Merli
MRMichele Rossi
Michele Rossi
DSDaniela Scuticchio
Daniela Scuticchio

8 January 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MBMarta Basaldella
Marta Basaldella
MRMichele Rossi
Michele Rossi
MGMarco Garzitto
Marco Garzitto
RRRoberta Ruffilli
Roberta Ruffilli
CFCarlo Francescutti
Carlo Francescutti
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
Background/Objectives: Adults with intellectual disability (ID) experience high rates of psychiatric comorbidity but often face diagnostic challenges and treatment barriers, leading to inappropriate psychotropic medication use. This study examined the extent to which specialized psychiatric assessment and improved diagnostic accuracy had an impact on medication management and clinical outcomes in adults with ID and co-occurring psychiatric disorders. Methods: This observational retrospective study analyzed medical records from 25 adults with ID who underwent specialized psychiatric assessment at a community-based service in Italy between January 2023 and January 2024. Psychopathological diagnoses were established according to Diagnostic Manual—Intellectual Disability, Second Edition (DM-ID2) criteria, based on clinical observation and a comprehensive assessment using validated instruments. Clinical outcomes were assessed using a psychometric tool encompassing multiple psychopathological and behavioral dimensions. Data on psychotropic prescriptions and side effects were also collected. Non-parametric analyses were performed, with significance set at α = 0.05. Results: The proportion of patients with a psychiatric diagnosis increased from 32% to 96% after specialized assessment (p < 0.001), with notable rises in depressive (0% to 32%), bipolar (8% to 36%), anxiety (4% to 24%), and impulse control (0% to 16%) disorders. First-generation antipsychotic prescriptions decreased (from 36% to 8%, p = 0.023), while antidepressant use increased (from 12% to 52%, p = 0.004). The mean number of side effects per patient declined from 1.6 to 0.5 (p < 0.001), particularly the elevated prolactin level and psychomotor retardation. Significant improvements were observed in symptom intensity and frequency across multiple domains, including aggression, mood disturbances, and compulsions (p < 0.001). Conclusions: In this single-center retrospective study, specialized psychiatric assessment was associated with improved diagnostic accuracy, medication management, and clinical outcomes in adults with ID. The increase in psychiatric diagnoses likely reflects improved identification, addressing key challenges in precision diagnosis for people with neurodevelopmental disorders. Although the overall number of prescribed medications remained stable, optimization of treatment regimens reduced first-generation antipsychotic use and related adverse effects. These findings indicates that access to specialized assessment and precision diagnosis could improve psychopharmacological interventions and outcomes for this vulnerable population, but larger, multi-center and longer-term studies are needed to confirm these results.

5 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MBMarta Basaldella
Marta Basaldella
MRMichele Rossi
Michele Rossi
MGMarco Garzitto
Marco Garzitto
RRRoberta Ruffilli
Roberta Ruffilli
CFCarlo Francescutti
Carlo Francescutti
MARCO BERTELLIMARCO BERTELLI
MARCO BERTELLI
Background/Objectives: Adults with intellectual disability (ID) experience high rates of psychiatric comorbidity but often face diagnostic challenges and treatment barriers, often leading to inappropriate psychotropic medication use. This study examined the extent to which specialised psychiatric assessment and improved diagnostic accuracy had an im-pact on medication management and clinical outcomes in adults with ID and co-occurring psychiatric disorders. Methods: This observational retrospective study ana-lysed medical records from 25 adults with ID who underwent specialised psychiatric as-sessment at a community-based service in Italy between January 2023 and January 2024. Psychopathological diagnoses were established according to Diagnostic Manu-al-Intellectual Disability 2nd version (DM-ID2) criteria, based on clinical observation and a comprehensive assessment using validated instruments. Clinical outcomes were as-sessed using a psychometric tool encompassing multiple psychopathological and behav-ioral dimensions. Data on psychotropic prescriptions and side effects were also collected. Non-parametric analyses were performed, with significance set at α=0.05. Results: The proportion of patients with a psychiatric diagnosis increased from 32% to 96% after spe-cialized assessment (p< 0.001), with notable rises in depressive (0% to 32%), bipolar (8% to 36%), anxiety (4% to 24%), and impulse control disorders (0% to 16%). First-generation an-tipsychotic prescriptions decreased (from 36% to 8%, p=0.023), while antidepressant use increased (from 12% to 52%, p=0.004). The mean number of side effects per patient de-clined from 1.6 to 0.5 (p< 0.001), particularly the elevated prolactin level, and psychomotor retardation. Significant improvements were observed in symptom intensity and frequency across multiple domains, including aggression, mood disturbances, and compulsions (p< 0.001). Conclusions: Specialised psychiatric assessment substantially improved diag-nostic accuracy, medication management, and clinical outcomes in adults with ID. The increase in psychiatric diagnoses reflects improved identification, addressing key chal-lenges in precision diagnosis for people with neurodevelopmental disorders. Evi-dence-based medication optimisation reduced inappropriate antipsychotic use and side effects. These findings support the need for specialised assessment and precision diagnosis to improve psycho-pharmacological interventions and outcomes for this vulnerable population.